Last Updated: November 16, 2026

Investigational Drug Information for BMS-963272

« Back to Dashboard


What is the development status for investigational drug BMS-963272?

BMS-963272 is an investigational drug.

There have been 4 clinical trials for BMS-963272. The most recent clinical trial was a Phase 1 trial, which was initiated on September 30th 2019.

The most common disease conditions in clinical trials are Liver Diseases, Fatty Liver, and Obesity. The leading clinical trial sponsors are Bristol-Myers Squibb and [disabled in preview].

There are eleven US patents protecting this investigational drug and sixty-seven international patents.

Recent Clinical Trials for BMS-963272
TitleSponsorPhase
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver DiseaseBristol-Myers SquibbPhase 1
A Study to Assess the Drug-drug Interaction of BMS-963272 and RosuvastatinBristol-Myers SquibbPhase 1
A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy AdultsBristol-Myers SquibbPhase 1

See all BMS-963272 clinical trials

Clinical Trial Summary for BMS-963272

Top disease conditions for BMS-963272
Top clinical trial sponsors for BMS-963272

See all BMS-963272 clinical trials

US Patents for BMS-963272

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BMS-963272 ⤷  Start Trial Aryl dihydropyridinones and piperidinone MGAT2 inhibitors Bristol Myers Squibb Co ⤷  Start Trial
BMS-963272 ⤷  Start Trial Aryl dihydropyridinones and piperidinone MGAT2 inhibitors Bristol Myers Squibb Co ⤷  Start Trial
BMS-963272 ⤷  Start Trial Bridged bicyclic compounds as farnesoid X receptor modulators Bristol Myers Squibb Co ⤷  Start Trial
BMS-963272 ⤷  Start Trial Aryl dihydropyridinones and piperidinone MGAT2 inhibitors Bristol Myers Squibb Co ⤷  Start Trial
BMS-963272 ⤷  Start Trial Substituted amide compounds useful as farnesoid X receptor modulators Bristol Myers Squibb Co ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BMS-963272

Drugname Country Document Number Estimated Expiration Related US Patent
BMS-963272 Argentina AR090041 2031-12-02 ⤷  Start Trial
BMS-963272 Australia AU2012345863 2031-12-02 ⤷  Start Trial
BMS-963272 Brazil BR112014013228 2031-12-02 ⤷  Start Trial
BMS-963272 Canada CA2857689 2031-12-02 ⤷  Start Trial
BMS-963272 Chile CL2014001437 2031-12-02 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.